The case for & against
Bull & Bear analysis
Bullish
Abeona Therapeutics, Inc. (NASDAQ: ABEO) is a biotechnology company specializing in innovative gene therapies for the treatment of rare diseases, particularly focusing on recessive dystrophic epidermolysis bullosa (RDEB) with its flagship product, ZivaSkin. The company has received FDA approval for ZivaSkin, which is the first autologous cell-based gene therapy designed to treat wounds in patients with RDEB. With strong insider ownership and anticipated rapid growth, Abeona aims to establish a strong presence in the rare disease market.
Bull says
- ↑Q1 net product revenue was $8.7 M, +262.5% YoY, indicating strong ZivaSkin traction
- ↑Forecasts include 40.5% annual revenue growth and 32.9% EPS growth
- ↑ZivaSkin covers 95% of insured lives with no payer denials recorded
- ↑High insider/institutional ownership supports momentum and profitability confidence
- ↑Median analyst target of $20 implies ~217% upside; consensus “Strong Buy”
- ↑Pipeline diversified by PSMA SIRT T-cell IND filing expected in H2 2027
Bear says
- ↓Q1 net loss reached $17.1 M vs $12 M a year ago, pressuring cash burn
- ↓Negative earnings yield suggests valuation concerns against peers
- ↓Onboarding of Qualified Treatment Centers remains slow, delaying patient treatments
- ↓High short interest signals skepticism and potential stock volatility
- ↓Regulatory delays in PSMA T-cell therapy could undermine future revenue
- ↓Smaller size versus large peers heightens competitive and execution risks
Investment themes with ABEO
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-13-2026neutral
Transcript signals
Bull points
- We have now activated six Qualified Treatment Centers, or QTCs, treated our fifth commercial patient with manufacturing underway for the sixth, and schedule additional patients throughout the current quarter.
- The recent acceleration of onboarding efforts of QTCs further underscores their conviction about the role that ZivaSkin will play in addressing the unmet needs of patients suffering from recessive dystrophic epidermolysis bullosa, or RDEV.
- Three of the ZivaSkin treatments reported to date took place in Q1, 2026, and translated into net revenue of $8.7 million for that quarter.
Bear points
- the process will improve. Oftentimes with gene therapy, especially high-cost gene therapy, the initial process of payer clearance, especially if a patient is traveling from out of state, there is additional layers of paperwork that need to be secured.
- Net loss for the quarter was $17.1 million, or 30 cents per basic and diluted common share, compared to a net loss of $12 million, or 24 cents per basic and diluted common share, in the first quarter of 2025. The year-over-year change primarily reflects increased commercial investment and the PSMA SIRT licensing transaction.
- Net loss for the quarter was $17.1 million, or 30 cents per basic and diluted common share, compared to a net loss of $12 million, or 24 cents per basic and diluted common share, in the first quarter of 2025. The year-over-year change primarily reflects increased commercial investment and the PSMA SIRT licensing transaction.
Read full transcript analysis ›